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Emerging techniques in the isolation and
characterization of extracellular vesicles and
their roles in cancer diagnostics and prognostics
Vijaya Sunkara,†a Hyun-Kyung Woo†a and Yoon-Kyoung Cho*b,a
Extracellular vesicles (EVs) are cell-derived nanovesicles, present in almost all types of body ﬂuids, which
play an important role in intercellular communication and are involved in the transport of biological
signals for regulating diverse cellular functions. Due to the increasing clinical interest in the role of EVs
in tumor promotion, various techniques for their isolation, detection, and characterization are being
developed. In this review, we present an overview of the current EV isolation and characterization
methods in addition to their applications and limitations. Furthermore, EVs as the potential emerging
biomarkers in cancer management and their clinical implementation are brieﬂy discussed.
1. Introduction
Cells release several types of extracellular vesicles (EVs) includ-
ing exosomes (40–120 nm in diameter, released during
the fusion of multi-vesicular endosomes with the plasma
membrane), microvesicles (100–1000 nm in diameter, formed
by direct budding from the plasma membrane) and apoptotic
bodies (1–5 μm in diameter, produced by cells due to apopto-
sis), which have been classified based on their biogenesis and
size.1–4 However, no analysis method or specific marker is cur-
rently available to distinguish the origin of these vesicles,
upon release into the extracellular matrix. Furthermore, it is
diﬃcult to diﬀerentiate between vesicles of a similar size when
they have been isolated together. Diﬀerent terminologies such
as EVs, microvesicles, or exosomes are used synonymously,
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particularly in the engineering community, for the isolated
nanovesicles and there is no consensus available to discrimi-
nate these vesicles. Therefore, in this review, we will use the
term “EVs” for all types of vesicles that measure <200 nm in
diameter, to make the review simple and understandable.
EVs are secreted by most cell types and are present in many
kinds of body fluids such as blood plasma, urine, amniotic
fluid, saliva, ascites, cerebrospinal fluid etc.5 At the time of
their discovery, they were thought to be involved in cellular
excretion of by-products and not much attention was given to
them until their participation in the immune response was
revealed.6,7 In 2007, it was shown that they mediate communi-
cation between cells due to the presence of functional RNAs.8
After that, research on EVs has grown exponentially focusing on
the development of new techniques for the isolation as well as
analysis of their composition and physiological functions.4,9,10
The functions of EVs depend on their origin as well as their
composition. Because they carry diverse membrane and cyto-
solic proteins, DNA, mRNA and miRNA, EVs are considered
potential biomarkers and are found to be involved in
both normal physiological processes and disease progression
in a pleiotropic manner, including the immune response,
antigen presentation, cell signaling, intercellular communi-
cation etc.2,9,11–20
In a tumor microenvironment, communication between
cancer and surrounding cells is essential for the tumors to
survive, metastasize and spread at distant sites (Fig. 1a). Here,
EVs play a vital role to transfer the tumor related genetic infor-
mation to the surrounding as well as distant cells and promote
tumor progress through metastatic niche formation, tumor
stroma generation and angiogenesis.9,11,20–24
In cancer research, intercellular communication through
miRNA is of particular interest, as they can regulate the gene
expression in recipient cells.25–32 However, the amount of
miRNA from EVs and its clinical importance remain a matter
of debate.23,33 In the literature, it is still not clear which
miRNA, the free miRNA or the exosomal miRNA, contributes
to a greater extent. Nonetheless, the advantage of isolating and
analyzing the exosomal RNAs is that the lipid bilayer protects
these molecules from degradation and allows eﬃcient recovery
from biological fluids.34,35
Isolation and analysis of pure EVs further enhance our
understanding of their roles in numerous biological events. As
EVs are gaining importance as biomarkers of tumor signa-
tures, their isolation with high purity is necessary, or else their
analysis could yield misleading results owing to the presence
of contaminants such as viruses, lipoproteins, large protein
aggregates, and other vesicles. Diﬀerential ultracentrifugation
is the conventional and most widely used method for the iso-
lation of diﬀerent vesicles from bio-fluids. However, it requires
a long time for isolation and diﬀerent particles with similar
physical properties can co-sediment. Thus, to overcome these
limitations, sucrose gradient purification and precipitation
reagents were developed. Numerous groups have been working
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Fig. 1 Schematic representation of cell-to-cell communication
through EVs and their isolation techniques. (a) EVs derived from cancer
cells transfer nucleic acids and proteins to the surrounding as well as
distant cells and promote niche formation, angiogenesis and metastasis.
(b) Isolation of EVs based on density (ultracentrifugation, sucrose gradi-
ent techniques, and precipitation reagents), size (ﬁltration through
membranes ﬁlters) and immunoaﬃnity (immunomagnetic separation,
microarray etc.).
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on developing microfluidic devices for the eﬃcient isolation of
pure EVs from bio-fluids.10
The size of EVs is much below the resolution of convention-
al fluorescence microscopes. Therefore, specialized equipment
is needed for the detection and analysis of the physical charac-
teristics of the EVs. At the same time, characterizing the exoso-
mal content is very important for understanding biological
functions of EVs as well as their roles in cancer development.
Several techniques are available and a combination of
diﬀerent methods is now being used for specific EV analysis.36
Recent reviews discuss EVs as an emerging biomarker for
intercellular communication and medical diagnostics.4,12–15 In
addition, the advances in isolation technologies of exosomes
using micro and nanofluidic devices were reviewed
recently.10,37 However, Liga et al. mainly focused on various
isolation techniques whereas Ko et al. reviewed the isolation as
well as detection methods, but the surface marker and protein
analysis was not discussed in detail. Here, we will focus on
recent trends in EV isolation and detection along with the
surface characterization methods and their roles in cancer
diagnostics and prognostics.
2. EV isolation methods
With the growing interest in EVs as potential biomarkers,
various isolation techniques have recently been developed.10
Furthermore, several research groups compared the eﬃciency
of available isolation techniques.38–40 Based on the principle
of their separation, the methods can be categorized into three
major classes: density-, size-, and immunoaﬃnity-based iso-
lation. Here, we have summarized the common isolation tech-
niques and recent trends along with new approaches.
2.1 Density-based isolation
As the name suggests, based on their density, particles are sep-
arated upon centrifugation. The techniques include ultracen-
trifugation and regular centrifugation with precipitation
reagents including commercialized kits (Fig. 1b, left). These
techniques enable the concentration of EVs rather than
isolation.
2.1.1 Ultracentrifugation (UC). Particles are separated by
applying diﬀerential centrifugation by varying the g force.
Cells and cellular debris are removed at a low g force; however,
a high g force of ∼200 000g sediments the EVs
(1.13–1.19 g mL−1).11,41 UC is a conventional and most
commonly used method for isolating EVs. However, it takes
∼5 h for isolating the exosomal pellet;5,42 moreover, it requires
special equipment, an ultracentrifuge, which might be unavail-
able in common laboratories in clinical settings. Other draw-
backs include ineﬃcient isolation and low recovery.38–40
Therefore, sucrose gradient centrifugation has been developed
to improve the purity and recovery.38 Nevertheless, it cannot
separate impurities like viruses43 and also it is time-consum-
ing owing to complicated sample-processing steps with
diﬀerential centrifugation.
2.1.2 Precipitation reagents. Recently, numerous commer-
cial kits that include precipitation reagents have been made
available for EV isolation. Here, the reagents reduce the solubi-
lity by lowering the hydration of EVs and lead to precipitation.
Using these kits, EVs can be separated at a low g force and
with higher yield than UC. However, these kits are too expens-
ive to be widely used and give low purity due to co-precipi-
Fig. 2 Devices for EV isolation and analysis. (a) RNA analysis using qPCR.58 (b) RNA and protein analysis using an electrochemical sensor.59 (c)
Protein analysis using photosensitizer beads.60 (d) Protein analysis using SPRi.42 Reproduced from ref. 42 and 58–60 with permission from the
Nature Publishing Group, Elsevier, and American Chemical Society.
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tation of proteins and EVs, as the solubility of almost all par-
ticles including EVs and proteins decreases equally when
using these materials.44 Moreover, the principles underlying
the mechanisms of these kits are unknown and some of the
kits have a very long incubation time of up to 12 h.39 In a com-
parative study, commercial kits such as Exo-Spin, Invitrogen,
and ExoQuick were found to have a higher recovery than UC,
while the PureExo kit has a recovery similar to that of UC.40,45
More recently, Shin et al. used polyethylene glycol and a
dextran aqueous two-phase system (ATPS) to isolate EVs.46
2.2 Size-based isolation
With exosomal size being known (<200 nm), EVs can be separ-
ated from cells and large debris by using nano-sized
membrane filters (Fig. 1b, middle). Filtration is an eﬀective
method for the removal of large debris including large vesicles
(above 200 nm in diameter), sub-cellular fractions, protein
aggregates, protein–nucleic acid aggregates, or plasma pro-
teins.47 Membranes with pore sizes of 0.2, 0.22, and 0.45 µm
and materials such as polyvinylidene fluoride48 and track-
etched polycarbonate are widely used to remove large
debris.49,50 The size based isolation techniques also enrich the
EVs from a complex mixture of samples but do not isolate
them specifically.
To enhance the purity, a combination of filtration and UC
is also commonly used.23,51–53 Muller et al. reported that this
combined method is better than using a UC based method,
diﬀerential centrifugation or the sucrose density gradient
method alone.47 Davies et al. applied the combined method
with pressure- and electrophoresis driven filtration for isolat-
ing and purifying EVs.54
2.2.1 Other approaches. Apart from membrane filtration,
several other approaches were proposed for size-based separ-
ation of EVs including acoustic waves and micro pillar-based
methods. Santana et al. used geometry to separate vesicles by
using the principles of deterministic lateral displacement
(DLD).55 Lee et al. used acoustic waves to isolate EVs in a
contact-free manner.56 Wang et al. used ciliated micro pillars
which possessed porous silicon nanowires on the sidewalls,
for multi-scale filtration by removing cellular debris as well as
proteins and other small objects.57
2.3 Aﬃnity-based isolation
To isolate EVs and study their relationship with cancer, new
isolation techniques utilizing microfluidics including paper-
based microfluidic devices, immunomagnetic beads, photo-
sensitizer beads etc. are being developed, based on immu-
noaﬃnity capture with antibodies specific to EVs (Fig. 1b,
right).38,49,61–64 The common exosomal markers are tetraspa-
nins including CD9, CD63, and CD81 and tumor-associated
markers are epithelial cell adhesion molecules (EpCAM),
IGF-1R α units (α-IGF-1R), CA125, CD41b, and E-cadherin.42,65
With the markers specific to exosomes, these methods aid in
the specific isolation of exosomes depending on the capture
antibodies used.
Various microfluidic devices are developed for selective iso-
lation and analysis on a single device by using a small sample
volume and within a short period of time. Due to their simpli-
city, these techniques can be applied to point of care (POC)
diagnostics. The microfluidic chip shown in Fig. 2a uses mag-
netic microbeads (3 µm in diameter) coated with anti-EGFR to
capture EVs from 100 µL of serum and has >93% capture
eﬃciency. It is an integrated method from EV isolation to RNA
analysis by qPCR in a single chip, which can be completed
within 2 h.58 Electric field-induced release and measurement
(EFIRM) was used for disrupting exosomes and monitoring
the released RNA/protein biomarkers, after capturing the EVs
by using anti-CD63-magnetic beads (Fig. 2b). With this device
and in vivo experiments, the authors confirmed that the H460-
CD63-GFP shed exosomes were transported to blood and
saliva.59 In another approach, He et al. used magnetic beads
coated with anti-EpCAM and anti-CA125 to isolate EVs in
volumes as low as 30 µL of plasma. It is an integrated analysis
technique including exosome capture and protein detection
using chemi-fluorescence in a single chip.65 Yoshioka et al.
used photosensitizer-beads to capture CD147- and CD9-posi-
tive EVs from 5 µL of serum, as shown in Fig. 2c. They could
complete EV capture and analysis within 1.5 h by using Exo-
Screen.60 Zhu et al. used an antibody microarray with surface
plasmon resonance imaging (SPRi) to capture and detect
tumor-derived EVs in real time and in a label-free manner, as
shown in Fig. 2d.42
Apart from the above techniques, the methods used for the
separation of nanoparticles have a high potential to be used in
the isolation of EVs from a complex mixture of samples. For
example, the Heller group developed a dielectrophoretic
method for the recovery of drug delivery nanoparticles as well
as cancer related biomarkers from plasma and blood.66,67 This
approach can be used for the isolation and detection of EVs
as well.
3. Detection and downstream
analysis of EVs
Novel detection methods are required to explore the physical
characteristics and biology of EVs. To analyze them, a combi-
nation of diﬀerent optical and non-optical techniques is uti-
lized, including electron microscopy, light scattering,
fluorescence, and molecular profiling. Here, we have summar-
ized the most commonly used methods, their applicability,
and limitations.
3.1 Size characterization
Size and morphological information can be obtained from
high-resolution imaging with electron microscopy utilizing
transmission electron microscopy (TEM), scanning electron
microscopy (SEM),70 or atomic force microscopy (AFM)
(Fig. 3a). The light scattering techniques (Fig. 3b–d) determine
the relative size distribution in a solution, the concentration,
and the zeta potential of the particles.
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3.1.1 TEM. Electron microscopy provides information on
the size and structure of the EVs. In most cases, concentrated
suspensions of EVs are applied and fixed on the grids. TEM is
usually combined with immunogold particles to detect EVs
specifically (Fig. 3a).23 It is a valuable tool to assess the size,
morphology, and presence of surface markers; however, the
concentration of EVs cannot be measured using this
technique.
3.1.2 AFM. AFM provides information regarding surface
features and has been used to assess the morphology of EVs.
Like TEM, AFM cannot be used for measuring the concen-
tration of EVs.71
3.1.3 Nanoparticle tracking analysis (NTA). It is a particle
tracking method for measuring the EV concentration and size
distribution.72 A laser beam is scattered by the particles in the
sample solution, and the mean velocity of each particle is cal-
culated on the basis of the Stokes–Einstein equation. The pro-
cedure for NTA analysis was optimized to minimize the
sources of errors.41,73 NTA was also used for the analysis of
fluorescently labeled EVs, derived from the blood of ovarian
cancer patients.74 Prior to NTA analysis, isolation and purifi-
cation are required to remove other particles that may have a
similar size. Using this technique, the vesicles with similar
Brownian motion cannot be distinguished from EVs and the
concentration calculated by this technique could include a
mixture of diﬀerent particles along with EVs. However,
currently, this is the most widely used method for analyzing
the size and concentration of EVs (Fig. 3b). From NTA analysis,
it was shown that breast cancer patients secrete higher concen-
tration of EVs than healthy donors.23
3.1.4 Dynamic light scattering (DLS). DLS is used for
measuring the size distribution49 and zeta potential of the EVs
(Fig. 3c and d). The principle of measuring the size is based
on the Brownian motion of the particles in solution; particles
diﬀuse at a speed related to their size; the smaller the particle,
the faster it moves. The particles in solution are illuminated
with a laser, and light scattering by the particles at a specific
angle is detected and the intensity changes are analyzed to
determine the size and its distribution. The diﬀusion rate of
the particles depends on the temperature; hence, care must be
taken to analyze all the samples at a constant temperature.
Zeta potential indicates the relative stability of the particles
in solution.77 It is determined by measuring their velocity
during the electrophoresis. Charged particles migrate towards
Fig. 3 Characterization of EVs. (a) Evaluation of morphology by transmission electron microscopy (TEM)23 and (b) size distribution and concen-
tration by nanoparticle tracking analysis (NTA),23 (c) size distribution by dynamic light scattering (DLS),49 (d) zeta potential measurements,68 (e)
enzyme-linked immunosorbent assay (ELISA),60 (f ) western blotting (WB),65 (g) Bradford assay for total protein quantiﬁcation (BCA) of EVs from non-
small-cell lung cancer (NSCLC) patients and healthy people,65 and (h) ﬂow cytometry (FC).69 Reproduced from ref. 23, 49, 60, 65, 68, and 69 with
permission from Elsevier, Nature Publishing Group, Royal Society of Chemistry and Japan Society of Applied Physics.
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the electrode under an applied electric field. The speed of the
particles is proportional to the field strength and the zeta
potential. The value of the zeta potential depends on the
temperature, pH, conductivity, and salt concentration of the
buﬀer used.
DLS analysis gives the average size of relatively mono-dis-
perse populations of isolated EVs, and it may not be a good
choice for a heterogeneous mixture of EVs. No diﬀerence was
observed between the average sizes of EVs derived from cancer
cells compared to those of EVs derived from normal cells.
However, the EVs derived from cancer cells showed higher zeta
potential than those derived from normal cells when measured
using an on-chip micro capillary electrophoresis system
(Fig. 3d).68
3.2 Surface markers and protein analysis
Several methods including ELISA, western blotting, Bradford’s
assay, and flow cytometry provide information on the presence
of proteins and specific surface markers (Fig. 3e–h). However,
standardization and optimization of the protocols are necess-
ary before being adapted for the analysis.
3.2.1 Enzyme-linked immunosorbent assay (ELISA).
ELISA-based techniques provide information on the presence
of surface markers and could be an indirect method to quan-
tify exosomal proteins. Recently, various commercially avail-
able ELISA kits were used to validate EV protein content. This
is a highly sensitive method for the quantitative analysis of
exosomal proteins (Fig. 3e).60 However, it is diﬃcult to find
specific antibody sets for each type of EV and this requires
several optimizations.
3.2.2 Western blotting (WB). Western blotting is a con-
venient method to show the presence of exosomal pro-
teins.50,65 Surface markers include tetraspanins (CD9, CD63,
CD81, CD82), MHC molecules, and cytosolic proteins or cyto-
skeletal proteins. Isolated EVs are lysed, and the proteins are
separated and analyzed. WB alone cannot determine the pres-
ence of EVs. However, it is very useful for identifying proteins
in purified exosomal samples (Fig. 3f).
3.2.3 Bradford assay. The total protein content of the puri-
fied EVs could be determined by the Bradford assay, which
provides an estimate of the amount of EVs secreted by the
cells. This technique cannot be applied for samples containing
other protein contaminants and needs extra purification steps
to remove contaminants. However, it is a very good tool to
diﬀerentiate between the total protein contents of EVs derived
from cancer patients and those derived from normal donors.
The EVs released from non-small-cell lung cancer (NSCLC)
patients showed higher protein content than those released
from healthy people (Fig. 3g).65
3.2.4 Flow cytometry (FC). This technique is applicable for
both qualitative and quantitative characterizations of EVs
(Fig. 3h).69,83,84 Standard FC detects vesicles above 200 nm;
Fig. 4 EVs in a tumor microenvironment and their protein/miRNA analysis for cancer diagnosis and prognosis. (a) Fluorescence images of cells pro-
ducing GFP-labelled EVs and their uptake by recipient cells.75 (b) Molecular proﬁling of protein markers.49 (c) (i & ii) Detection and prognosis of
miR1246 in esophageal squamous cell carcinoma (ESCC).76 (iii & iv) Detection and prognosis of miR-19a expression in colorectal cancer (CRC).32
Reproduced from ref. 32, 49, 75 and 76 with permission from Elsevier and the Nature Publishing Group.
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therefore, it cannot analyze the EVs directly. To overcome this
limitation EVs are fixed on large beads, labeled with fluoro-
phore-conjugated antibodies, and then analyzed by FC. Analy-
sis by fixing them on beads provides information on the
relative presence of surface proteins and does not quantify the
amount of EVs. Lacroix et al. reviewed the technical improve-
ments proposed to overcome the limitations of FC measure-
ment.85 Thus, it is a powerful technique to analyze EVs but the
interpretation should be made cautiously by considering its
limitations.
3.2.5 Miscellaneous techniques. A few techniques such as
surface plasmon resonance,86 fluorescence fluctuation spec-
troscopy,87 the nanoplasmonic assay,88 tunable resistive pulse
sensing,89 electrohydrodynamic induced nanoshearing,90
and EFIRM59 were used for the sensitive detection of EVs.
In addition, the use of special techniques such as micro-
nuclear magnetic resonance, resistive pulse sensing, Raman
microspectroscopy, small-angle X-ray scattering etc. for the
detection of EVs was reviewed recently.36 However, each tech-
nique needs to be validated for its application in the detection
of specific EVs.
3.3 Molecular analysis
3.3.1 Fluorescence imaging. Given the information that
cancer cell derived EV has a role in metastatic niche formation,
tracking their intercellular communication may contribute to
understanding the mechanism of tumor progression and
metastasis (Fig. 4a). To trace EVs, a lipophilic dye for capturing
a lipid bilayer of EV or a fluorescent probe fused with EV
specific protein markers is useful. Lipophilic carbocyanines
including PKH67, PKH26, DiI and DiR and the green fluo-
rescent protein (GFP) or red fluorescent protein (RFP) tagged
exosomal marker CD63 are widely used for in vivo and in vitro
imaging.75,91 Zomer et al. used in vivo imaging to study
migratory behavior and metastatic capacity through uptake
of EV.91
3.3.2 Molecular profiling. It has been reported that EVs
contain protein and diverse RNA cargo including short
sequences of 20–200 nt (like miRNA and fragments of mRNA)
and longer species like 18S and 28S rRNA.97 Molecular profil-
ing of these components has been used to examine their
relationship with cellular origin and their application in
cancer diagnostics.49,58
Table 1 Clinical importance of exosomal miRNA in cancers
Cancer types Sample type EV isolation method RNA isolation
Exosomal contents
(miRNA) Clinical value
Esophageal
squamous cell
carcinoma
(ESCC)
Serum Ultracentrifugation
(100 000g)
TRIzol reagent, mirVana
PARIS kit
miR-1246 Upregulation in patients76
Serum 0.45 µm filtration,
ExoQuick
mirVana microRNA
isolation kit (Life Tech)
miR-21 Upregulation in patients
than benign disease48
Colorectal
cancer (CRC)
Serum Ultracentrifugation
(100 000g)
Acid-guanidine-phenol-
chloroform
miR-19a and 92a Upregulation in patients.
Higher expression is
indicative of poor
prognosis32
Serum 0.2 µm filtration,
ultracentrifugation
(120 000g)
TRIzol reagent
(Invitrogen), RNeasy Mini
spin column (Qiagen),
Agilent miRNA labeling
reagent
Let-7a, miR-1229,
1246, 150, 21,
223, 23a
Upregulation in patients26
Hepato-cellular
carcinoma
(HCC)
Serum 0.22 µm filtration,
ultracentrifugation
(100 000g)
miRNeasy Mini Kit
(Qiagen)
miR-718
(tumor-suppressive
miRNA)
Progression and
recurrence.
Downregulation in
patients with recurrence
compared to that observed
in those without
recurrence78
Serum Total exosome isolation
reagent (Invitrogen)
Isothiocyanate-phenol/
chloroform extraction
procedures
miR-21 Upregulation in patients
compared to that
observed in patients with
hepatitis or in healthy
controls79
Breast cancer Serum ExoQuick exosome
precipitation solution
(BioCat)
mirVana PARIS kit
(Life Tech)
miR-101, 372, 373 Upregulation in patients80
Cervical cancer Cervicovaginal
lavages
Ultracentrifugation mirVana microRNA
isolation kit (Ambion)
miR-21, 146a Upregulation in patients29
Pancreatic
cancer
Serum Sucrose-gradient
centrifugation
(100 000g)
miRNeasy Mini Kit
(Qiagen)
miR-1246, 4644, 3976,
4306
Upregulation in patients81
Prostate cancer Plasma ExoQuick exosome
precipitation solution
(SBI)
miRNeasy Micro Kit
(Qiagen)
miR-1290, miR-375 Upregulation in patients.
Their levels are
associated with a poor
survival rate82
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Quantitative reverse transcription polymerase chain
reaction (qRT PCR), miRNA arrays, bioanalyzers and mass
spectrometry are widely used for profiling exosomal
cargo.45,97,98 Wyss et al. used single fluctuation analysis to
profile both the size and the relative expression level of a par-
ticular membrane receptor in individual EV.87 Rekker et al.
compared isolation methods for microRNA profiling, showing
that both UC and ExoQuick precipitation methods are suitable
for profiling.45
Im et al. conducted molecular profiling of ovarian cancer
protein markers, as shown in Fig. 4b. Through this, ovarian
cancer cells and benign cells could be diﬀerentiated from each
other.49 Ueda et al. established mass spectrometric immuno-
assay monolith pipette tips to profile serum EV, identifying
CD91 as a lung adenocarcinoma specific antigen on EV.98
3.3.3 Clinical analysis. Clinical analysis of EVs has
increased recently because it is an enriched source of bio-
markers containing nucleic acids (Table 1) and proteins
(Table 2) for diagnosing cancer. Especially, Melo et al. detected
pancreatic cancer with an area under the curve (AUC) of 1.0
(sensitivity and specificity of 100%) using Glypican-1 which is
membrane protein specifically enriched in cancer-cell derived
EVs.92 Yoshioka et al. detected colon cancer with an AUC of
0.820 using double positive of CD147/CD9 EV.60 Gabriel et al.
detected prostate cancer using tumor suppressor phosphatase
and tensin homolog (PTEN) which is expressed only in the EVs
from the plasma of patients.95 Ueda et al. detected lung adeno-
carcinoma with an AUC of 0.724 (sensitivity: 60.0% and speci-
ficity: 89.0%) using exosomal CD91 and with an AUC of 0.882
(sensitivity: 71.4% and specificity: 91.8%) using a combination
of CEA (classical biomarker) and exosomal CD91.98 With
receiver operating characteristic curve analysis of miR-1246
(Fig. 4c (i)), esophageal squamous cell carcinoma (ESCC) can
be detected, with AUC = 0.754 (sensitivity: 71.3% and speci-
ficity: 73.9%).76 The expression levels of miR-19a are studied at
diﬀerent stages of cancer for diagnosing colorectal cancer
(CRC) as shown in Fig. 4c (iii).32 In addition, they have a prog-
nostic value in each case, providing a lower survival rate with
higher miRNA expression (Fig. 4c (ii) and (iv)).32,76
4. Conclusions and perspectives
EVs contain a substantial amount of genetic information that
could be transferred to other cells, thereby promoting the pro-
gression of metastatic tumors in cancer patients. Several
methods are being developed to isolate and analyze EVs to
understand their physiological functions. However, still there
is a need for new technologies that could isolate pure EVs
from a mixture of various particles and contaminants.
One of the biggest issues in the EV research is the lack of
proper terminology and methodology. Though we termed all
vesicles as EVs in this article, there should be a clear demar-
cation for each vesicle and the data regarding their content,
specific markers and physiological functions should be
obtained and compared for diﬀerent kinds of vesicles.
Another major issue in this field is diﬀerentiating between
microvesicles and exosomes of similar size. Any vesicles that
share size, density, or scattering properties would interfere
with the isolation and detection of other vesicles. Devices that
specifically capture a particular type of vesicles should be
developed.
In addition, eﬃciency in terms of purification and quantifi-
cation of the currently available isolation procedures is
unknown. A standard must be developed to compare the data
of diﬀerent sets of experiments.
Apart from all these issues, demonstrating the physiological
functions of EVs in vivo is a major challenge. Thus far, data
regarding EVs have been obtained from in vitro studies and
very little is known about their function in vivo. Nevertheless,
Table 2 Clinical importance of exosomal protein markers in cancers
Cancer types
Sample
type EV isolation method Protein assay
Exosomal contents
(protein) Clinical value
Pancreatic
cancer
Serum 0.2 µm filtration,
ultracentrifugation (150 000g)
Ultra-performance liquid
chromatography-mass
spectrometry (UPLC-MS)
Glypican-1 (GPC1) 100% sensitivity and
specificity for detecting
pancreatic cancer92
Saliva Magnetic beads based capture Western blotting Apbblip, Daf2, Foxp1,
Incenp, BCO31781,
Aspn, and Gng2
Upregulation in pancreatic
cancer-derived exosomes
from tumor-bearing
mice93
Acute myeloid
leukemia
(AML)
Plasma 0.22 µm filtration, Bio-Gel
A50 m columns (Bio-Rad),
ultracentrifugation (100 000g)
Immunoaﬃnity capture CD34 Upregulation in patients94
Colon cancer Serum Immunoaﬃnity capture ExoScreen CD147, CD9 Upregulation of double
positive (both CD147 and
CD9) in patients60
Prostate
cancer
Plasma Ultracentrifugation (100 000g) Western blotting Phosphatase and
tensin homolog
(PTEN)
Only detected in cancer
patients95
Bladder
cancer
Urine 0.2 µm filtration,
ultracentrifugation (100 000g)
Western blotting EDIL-3/Del1 Upregulation in patients
associated with tumor
grade96
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increasing evidence suggests that EVs are emerging bio-
markers for cancer diagnosis and therapeutics.
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